Boehringer Ingelheim Kg

Dr. Karl Thomae Gmbh

Boehringer Ingelheim Gmbh

Karl Thomae Gmbh

Gunter Schingnitz

Joachim Mierau

Karl-Heinz Weber

Franz J Kuhn

Claus S Schneider

Erich Lehr

Werner Stransky

Helmut Ensinger

Rudolf Hurnaus

Walter Kobinger

Ludwig Pichler

Dieter Hinzen

Rudolf Bauer

Ulrike Kufner-Muhl

Gerhard Walther

Herbert Merz

Gerhart Griss, Deceased

Matthias Grauert

Manfred Reiffen

Wolfgang Grell

Dietrich Arndts

Michael Entzeroth

Robert Sauter

Rainer Sobotta

Ilse Streller

Enzio Muller

Alexander Walland

Gerhard Waither

Gerhard Walther, Deceased

Oleh Hornykiewicz

The invention relates to new xanthine derivatives of general formula I, processes for preparing them and their use as pharmaceutical compositions.

Xanthine derivatives with adenosine-antagonistic activity

Bornyl xanthine derivatives with adenosine-antagonistic activity

New xanthine compounds of formula I: ##STR1## wherein the substituents are defined herein, which xanthines are useful as adenosine antagonists.

8-substituted 1,3-dialiphaticxanthine derivatives

Xanthines of the formula I ##STR1## wherein R.sub.1 is a C.sub.1 -C.sub.4 alkyl group:

The invention relates to new tetrahydropyridine derivatives, processes for preparing them and their use as pharmaceutical compositions with cholinomimetic properties.

Tetrahydropyridine derivatives

The invention relates to novel 2,5-diaminotetralines of the formula: ##STR1## wherein R1, R2, R3 and R4 are defined herein, processes for preparing them and their use in pharmaceutical compositions. The novel 2,5-diaminotetralines are useful in treating diseases caused by disorders of the dopaminergic systems.

Method of treating disorders of the dopaminergic systems using

The present invention relates to new 4,5,7,8-tetrahydro-6H-thiazolo[5,4-d]azepines of general formula II ##STR1## wherein the substituents are defined herein below, which compounds have valuable pharmacological properties, namely selective effects on the dopaminergic system which are achieved by stimulating (predominantly D2) dopamine receptors.

4,5,7,8-tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and

Novel compounds having the general formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein. These compounds are useful in the treatment of schizophrenia.

Use of 2,7-diamino-1,2,3,4-tetrahydronaphthalenes as medicaments, new

Tetrahydrobenzothiazole derivatives of the formula ##STR1## wherein n is 1, 2 or 3 and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are defined substituents, said derivatives (I) being suitable as active compounds for treating parkinsonism or Parkinson's Disease.

Tetrahydrobenzothiazoles, and the preparation and use thereof

This invention relates to new tetrahydrobenzthiazoles of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the above mentioned phenyl nucleic may each be substituted by 1 or 2 halogen atoms, R.sub.2 represents a hydrogen atom or an alkyl group, R.sub.3 represents a hydrogen atom, an alkyl group a cycloalkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the phenyl nucleus may be substituted by fluorine, chlorine or bromine atoms, R.sub.4 represents a hydrogen atom, an alkyl group, an alkyl or alkenyl group, or R.sub.3 and R.sub.4 together with the nitrogen atom between them represent a pyrrolidino, piperidino, hexamethyleneimino or morpholino group, the enantiomers and the acid addition salts thereof. The compounds of general formula I above in which one of the groups R.sub.1 or R.sub.3 or both groups R.sub.1 and R.sub.3 represent an acyl group are valuable intermediate products for preparing the other compounds of general formula I which have valuable pharmacological properties. The new compounds may be prepared using methods known per se.

Tetrahydro-benzthiazoles, the preparation thereof and their use as

The invention relates to the use of 2-[N-(2,6-dichlorophenyl)-N-allylamino]-2-imidazoline as a cytoprotective agent.

Use of 2-(N-2,6-dichlorophenyl-N-allylamino)-2-imidazoline as

This invention relates to new tetrahydrobenzthiazoles of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the above mentioned phenyl nuclei may each be substituted by 1 or 2 halogen atoms.

This invention relates to new tetrahydrobenzthiazoles of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkenyl or alkynylk group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the above mentioned phenyl nuclei may each be substituted by 1 or 2 halogen atoms,

The invention describes the use of 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine and the acid addition salts thereof for the treatment of Parkinson's disease or Parkinsonism.

Growing community of inventors

Bad Kreuznach, Germany

Gunter Schingnitz